Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
enGene logo — Pioneering mucosal immunotherapy to combat chronic diseases...

enGene

Pioneering mucosal immunotherapy to combat chronic diseases and regenerate insulin secretion for diabetes management

Founded 1999 11-50 employees Post-IPO Equity Biotechnology, Health Care

General Information

Company Name enGene
Founded Year 1999
Founders / Decision Makers
Team member Team member Team member Team member
Employees 11-50
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with enGene. To contact enGene, visit engene.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does enGene compare?

A PDF of enGene and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting enGene soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About enGene

enGene is a biotechnology startup pioneering mucosal immunotherapy to combat chronic diseases and regenerate insulin secretion for diabetes management. Established in 1999, the company focuses on developing a mucosal immunotherapy platform to target inflammatory bowel disease and diabetes. It features a versatile nucleotide delivery technology that specifically addresses mucosal tissues, thereby modulating protein expression levels to manage various chronic conditions. This unique capability allows medical professionals to regenerate natural, meal-regulated insulin secretion from the gut in diabetes patients. The company operates within the industries of Biotechnology and Health Care. As of now, specific details regarding the startup's headquarters, last investment, and the investors involved in the last investment are not available.

Business keywords: mucosal immunotherapy, inflammatory bowel disease, diabetes management, nucleotide delivery technology, chronic diseases treatment, protein expression modulation, insulin secretion regeneration, gene therapy, urology, oncology, immunotherapy, bladder cancer, DNA, RNA, genetic medicines

No funding data available for enGene yet.

enGene Alternatives & Competitors

View All Alternatives
enGene vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care
enGene vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
enGene vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
34 employees
Biotechnology, Health Care
View all alternatives

FAQ About enGene

Pioneering mucosal immunotherapy to combat chronic diseases and regenerate insulin secretion for diabetes management
enGene was founded in 1999.
enGene operates in Biotechnology and Health Care. Its work centres on mucosal immunotherapy, inflammatory bowel disease, diabetes management and nucleotide delivery technology.
enGene has approximately 11-50 employees.
Top alternatives and competitors to enGene include TransCode Therapeutics, Inc., Upstream Bio, Affinia Therapeutics, MetiMedi Co., Ltd., Homology Medicines. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
enGene and TransCode Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for enGene, https://bouncewatch.com/company/engene, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes